Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biomarkers for In Vivo Assessment of Transporter Function
Fabian Müller, Ashish Sharma, Jörg König, et al.
Pharmacological Reviews (2018) Vol. 70, Iss. 2, pp. 246-277
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium
Xiaoyan Chu, Mingxiang Liao, Hong Shen, et al.
Clinical Pharmacology & Therapeutics (2018) Vol. 104, Iss. 5, pp. 836-864
Open Access | Times Cited: 177
Clinical Studies on Drug–Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation
Aleksi Tornio, Anne M. Filppula, Mikko Niemi, et al.
Clinical Pharmacology & Therapeutics (2019) Vol. 105, Iss. 6, pp. 1345-1361
Open Access | Times Cited: 149
Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions
Arne Gessner, Jörg König, Martin F. Fromm
Clinical Pharmacology & Therapeutics (2019) Vol. 105, Iss. 6, pp. 1386-1394
Closed Access | Times Cited: 107
Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs
Daiki Mori, Emi Kimoto, Brian Rago, et al.
Clinical Pharmacology & Therapeutics (2019) Vol. 107, Iss. 4, pp. 1004-1013
Open Access | Times Cited: 89
Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development
Yurong Lai, Xiaoyan Chu, Li Di, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 6, pp. 2751-2777
Open Access | Times Cited: 58
A Pilot Study To Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy Participants
Hong Shen, Runlan Huo, Yueping Zhang, et al.
Journal of Pharmacology and Experimental Therapeutics (2024) Vol. 390, Iss. 2, pp. 162-173
Open Access | Times Cited: 11
Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug–Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective
Hee Jae Choi, Shilpa Madari, Fenglei Huang
Clinical Pharmacokinetics (2024) Vol. 63, Iss. 6, pp. 735-749
Open Access | Times Cited: 9
Clinical Assessment of Drug Transporter Inhibition Using Biomarkers: Review of the Literature (2015–2024)
David Rodrigues, Stephanie Wezalis
The Journal of Clinical Pharmacology (2025)
Closed Access | Times Cited: 1
Is N1-Methylnicotinamide a Good Organic Cation Transporter 2 (OCT2) Biomarker?
Anoud Ailabouni, Gautam Vijaywargi, Sandhya Subash, et al.
Metabolites (2025) Vol. 15, Iss. 2, pp. 80-80
Open Access | Times Cited: 1
In vitro and in vivo methods to assess pharmacokinetic drug– drug interactions in drug discovery and development
Chuang Lu, Li Di
Biopharmaceutics & Drug Disposition (2019) Vol. 41, Iss. 1-2, pp. 3-31
Open Access | Times Cited: 58
Identification and characterization of endogenous biomarkers for hepatic vectorial transport (OATP1B3-P-gp) function using metabolomics with serum pharmacology
Yong-wen Jin, Yanrong Ma, Mingkang Zhang, et al.
Amino Acids (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 6
Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers
Daiki Mori, Yushi Kashihara, Takashi Yoshikado, et al.
Drug Metabolism and Pharmacokinetics (2018) Vol. 34, Iss. 1, pp. 78-86
Closed Access | Times Cited: 58
Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition
Hong Shen, Lisa J. Christopher, Yurong Lai, et al.
Drug Metabolism and Disposition (2018) Vol. 46, Iss. 8, pp. 1075-1082
Open Access | Times Cited: 52
Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects
Hong Shen, Vinay K. Holenarsipur, T. Thanga Mariappan, et al.
Journal of Pharmacology and Experimental Therapeutics (2018) Vol. 368, Iss. 1, pp. 136-145
Open Access | Times Cited: 52
Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine
Sabrina Wiebe, Thomas Gießmann, Kathrin Hohl, et al.
Clinical Pharmacokinetics (2020) Vol. 59, Iss. 12, pp. 1627-1639
Open Access | Times Cited: 44
Identification of Glycochenodeoxycholate 3‐O‐Glucuronide and Glycodeoxycholate 3‐O‐Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers
Mikko Neuvonen, Päivi Hirvensalo, Aleksi Tornio, et al.
Clinical Pharmacology & Therapeutics (2020) Vol. 109, Iss. 3, pp. 646-657
Open Access | Times Cited: 40
Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans
Mikko Neuvonen, Aleksi Tornio, Päivi Hirvensalo, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 110, Iss. 6, pp. 1622-1632
Open Access | Times Cited: 33
Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug Delivery
Kristiina M. Huttunen, Tetsuya Terasaki, Arto Urtti, et al.
Pharmaceutical Research (2022) Vol. 39, Iss. 7, pp. 1363-1392
Open Access | Times Cited: 28
Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan‐Transporter Inhibition Signatures
A. David Rodrigues
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 5, pp. 986-1002
Closed Access | Times Cited: 23
N1‐Methylnicotinamide as Biomarker for MATE‐Mediated Renal Drug–Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid
Fabian Müller, Kathrin Hohl, Sascha Keller, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 113, Iss. 5, pp. 1070-1079
Open Access | Times Cited: 15
A Metabolomic Analysis of Sensitivity and Specificity of 23 Previously Proposed Biomarkers for Renal Transporter‐Mediated Drug‐Drug Interactions
Arne Gessner, Fabian Müller, Pia Wenisch, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 5, pp. 1058-1072
Open Access | Times Cited: 14
The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition–Progress from 2016 to 2023
Yurong Lai
Drug Metabolism and Disposition (2023) Vol. 51, Iss. 8, pp. 950-961
Open Access | Times Cited: 13
Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I
S. Barnett, Kayode Ogungbenro, Karelle Ménochet, et al.
Journal of Pharmacology and Experimental Therapeutics (2018) Vol. 368, Iss. 1, pp. 125-135
Open Access | Times Cited: 43
Renal Transporter‐Mediated Drug‐Biomarker Interactions of the Endogenous Substrates Creatinine and N1‐Methylnicotinamide: A PBPK Modeling Approach
Denise Türk, Fabian Müller, Martin F. Fromm, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 112, Iss. 3, pp. 687-698
Open Access | Times Cited: 19
Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein–Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo
Yueping Zhang, Petia Shipkova, Bethanne M. Warrack, et al.
Drug Metabolism and Disposition (2023) Vol. 51, Iss. 7, pp. 851-861
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top